TAE684 (NVP-TAE684)

製品コードS1108

TAE684 (NVP-TAE684)化学構造

分子量(MW):614.2

TAE684 (NVP-TAE684)は一種の有効で、選択性的なALK阻害剤で、無細胞試験でIC50値が3 nMです。TAE684 (NVP-TAE684)は、ALKに作用する選択性はInsRに作用する選択性より100倍が高くなります。

サイズ 価格 在庫  
USD 201 あり
USD 365 あり
USD 970 あり

カスタマーフィードバック(4)

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

製品安全説明書

ALK阻害剤の選択性比較

生物活性

製品説明 TAE684 (NVP-TAE684)は一種の有効で、選択性的なALK阻害剤で、無細胞試験でIC50値が3 nMです。TAE684 (NVP-TAE684)は、ALKに作用する選択性はInsRに作用する選択性より100倍が高くなります。
靶点
ALK [1]
(Cell-free assay)
3 nM
In vitro試験

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLWXoVbUUN3ME2wMlAxODB4MEOg{txO MoP6V2FPT0WU
SF539 NHu0O3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMECwOVY1KM7:TR?= NFf1RZVUSU6JRWK=
DEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7aSoxSUUN3ME2wMlAxODl{NzFOwG0> Mmm5V2FPT0WU
NB1 NHzEOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13z[2lEPTB;MD6wNFE3OiEQvF2= M3rIS3NCVkeHUh?=
SR NIOwVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rGcmlEPTB;MD6wNFI4PyEQvF2= MX3TRW5ITVJ?
KARPAS-299 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLoTWM2OD1yLkCyN|g1KM7:TR?= NUfKV2VlW0GQR1XS
MHH-CALL-2 M4fW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSydphKSzVyPUCuNFI6PTJizszN Mn:5V2FPT0WU
SU-DHL-1 NUG4ZXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMES4OlUh|ryP NXG3U2J3W0GQR1XS
A4-Fuk NHnXNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjaWlQ{UUN3ME2wMlA2PTZ3IN88US=> NGrFRoFUSU6JRWK=
EW-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGwTWM2OD1yLkGwNlU3KM7:TR?= MV\TRW5ITVJ?
NOS-1 NV3RZ2hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMUCyPVQh|ryP NHrGWmpUSU6JRWK=
EW-16 NYrTbWVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLRTWM2OD1yLkGwOVY5KM7:TR?= NVPTWmZ3W0GQR1XS
TE-11 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnSTWM2OD1yLkG2NFk3KM7:TR?= NX3XPJJoW0GQR1XS
SW982 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXwT|h2UUN3ME2wMlE3PDd6IN88US=> MVHTRW5ITVJ?
LAN-6 NFvsdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3lTWM2OD1yLkG3OFQ{KM7:TR?= NVzaNXZXW0GQR1XS
MZ1-PC NV[0dnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq5UlJKSzVyPUCuNVc5OzVizszN M2P6NHNCVkeHUh?=
KS-1 M3jLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvqNlFKSzVyPUCuNVk{PDNizszN NF;pU5ZUSU6JRWK=
PSN1 M4HxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSySllmUUN3ME2wMlE6PjNzIN88US=> M2\LZ3NCVkeHUh?=
LC-2-ad NUfkVZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2cWlEPTB;MD6xPVY6OiEQvF2= MVHTRW5ITVJ?
COLO-320-HSR MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUm3O|Yh|ryP NHWwSIZUSU6JRWK=
OPM-2 MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj2RpJKSzVyPUCuNlI3PjlizszN MlflV2FPT0WU
SK-NEP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf1VY8zUUN3ME2wMlI{PTJ2IN88US=> MY\TRW5ITVJ?
ALL-PO M{HNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXpdGliUUN3ME2wMlI1PTJ2IN88US=> M4m3XXNCVkeHUh?=
CMK MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMkW1N{DPxE1? NYXWPFNnW0GQR1XS
NCI-H1648 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMke4OVUh|ryP MXPTRW5ITVJ?
SIG-M5 NUHJXnBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXi[GVHUUN3ME2wMlI6OTV7IN88US=> NI\Nd4RUSU6JRWK=
TGBC24TKB NVPz[25ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHQO5VKSzVyPUCuN|AzOThizszN M17WZ3NCVkeHUh?=
DOHH-2 NH\ocYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HiTmlEPTB;MD6zNVIxPCEQvF2= NV;1OWFlW0GQR1XS
NB69 NVrs[lNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DEWGlEPTB;MD6zNVc5PyEQvF2= MYHTRW5ITVJ?
MFH-ino NEHSbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHmR2FOUUN3ME2wMlMzPTJ|IN88US=> M1HGU3NCVkeHUh?=
KP-N-RT-BM-1 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O3b2lEPTB;MD6zN|EzOyEQvF2= M4e5Z3NCVkeHUh?=
MONO-MAC-6 M3qyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHGTWM2OD1yLkOzNlkyKM7:TR?= NWO4OFd4W0GQR1XS
ATN-1 M2nFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHre5pKSzVyPUCuN|M{ODNizszN MV;TRW5ITVJ?
NTERA-S-cl-D1 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HLb2lEPTB;MD6zN|M6PiEQvF2= NGK2bIxUSU6JRWK=
L-540 NHTvVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfJZlZKSzVyPUCuN|Y6QDhizszN NFTS[ppUSU6JRWK=
GB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfnTWM2OD1yLkO4PFY4KM7:TR?= M4LBe3NCVkeHUh?=
MV-4-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{m0OFYh|ryP M1fpS3NCVkeHUh?=
KG-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fk[2lEPTB;MD6zPVU3OSEQvF2= NY\yVItNW0GQR1XS
OVCAR-4 M3vNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNEC1Olkh|ryP MVfTRW5ITVJ?
NEC8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS1NVZoUUN3ME2wMlQyOjl{IN88US=> MV7TRW5ITVJ?
SK-MM-2 NVj2eY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNEG2NFkh|ryP MV7TRW5ITVJ?
TE-8 M3eyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNEK4PEDPxE1? NFTRfo5USU6JRWK=
697 NIG0d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD1yLkSzNlE2KM7:TR?= MXvTRW5ITVJ?
NB14 NESxe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3iTWM2OD1yLkSzPFI3KM7:TR?= MlPBV2FPT0WU
GDM-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNEexNVYh|ryP Mlm2V2FPT0WU
HUTU-80 NUTpZZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TP[2lEPTB;MD60O|M4PSEQvF2= M1\rcHNCVkeHUh?=
HL-60 M17NU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PxN2lEPTB;MD60PFE1OiEQvF2= MX3TRW5ITVJ?
OCI-AML2 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S5Z2lEPTB;MD60PFMzQCEQvF2= M16z[nNCVkeHUh?=
ML-2 NInIZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS3dpRKSzVyPUCuOFkxOzFizszN MlP1V2FPT0WU
ES4 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHE[VZ{UUN3ME2wMlQ6OTB7IN88US=> Mny4V2FPT0WU
NCI-H747 NEnyS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\QTWM2OD1yLkS5PFkh|ryP MX3TRW5ITVJ?
RL95-2 NIf1bnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6yTWM2OD1yLkWwNVEzKM7:TR?= MmLPV2FPT0WU
TE-15 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNUGxNlQh|ryP M{\6XXNCVkeHUh?=
TE-12 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDZe|lCUUN3ME2wMlU{OzR7IN88US=> NXPWWI41W0GQR1XS
LB1047-RCC MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jmRWlEPTB;MD61OFU1QSEQvF2= NWrkOIh[W0GQR1XS
LB831-BLC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7jfYdWUUN3ME2wMlU2ODJ|IN88US=> NHzHcYRUSU6JRWK=
NCI-H1355 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNUWxPFQh|ryP MknIV2FPT0WU
CTV-1 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwNUW2NlQh|ryP NUPWZ|hxW0GQR1XS
RXF393 NXLnXZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNUW3PVQh|ryP NUDmRmhzW0GQR1XS
SW872 NW\3ZlVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mydGlEPTB;MD61OlczPCEQvF2= MkXhV2FPT0WU
MPP-89 NHTKe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTRTWM2OD1yLkW3PFg1KM7:TR?= NEHGcXBUSU6JRWK=
RPMI-8226 NYfldWx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPS[nZbUUN3ME2wMlY{PTJ4IN88US=> NUjCPZZxW0GQR1XS
LS-1034 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkO1PEDPxE1? NGPnPWtUSU6JRWK=
SJSA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNkO3NlUh|ryP NWrPeGJsW0GQR1XS
HOP-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVTGlEPTB;MD62OVA{OyEQvF2= MX;TRW5ITVJ?
KGN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNk[xOlgh|ryP MX;TRW5ITVJ?
D-336MG M{P4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNk[xOlkh|ryP M3\tfnNCVkeHUh?=
LS-411N NVLh[5BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOO5loUUN3ME2wMlY4PDZ{IN88US=> NEDSNIpUSU6JRWK=
TE-1 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwNkmwO|Qh|ryP NHvXNVRUSU6JRWK=
LB996-RCC NWn4PINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSwTWM2OD1yLk[5N|g6KM7:TR?= M4TFcnNCVkeHUh?=
TE-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL6TWM2OD1yLkexOFk3KM7:TR?= MkPxV2FPT0WU
NCI-SNU-16 M1LoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfXWGZKSzVyPUCuO|I3PjRizszN NGPLd5BUSU6JRWK=
ES8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHiNXhKSzVyPUCuO|Q6PzVizszN MUTTRW5ITVJ?
COLO-800 NHPrc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX6TWM2OD1yLke2Olk2KM7:TR?= NYPHTXZmW0GQR1XS
ES6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M332b2lEPTB;MD63O|U2QSEQvF2= NWjkOXhPW0GQR1XS
L-363 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[5TWM2OD1yLkiyN|c2KM7:TR?= M1vjW3NCVkeHUh?=
NMC-G1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\KTWM2OD1yLkizNlM{KM7:TR?= M2DzU3NCVkeHUh?=
LU-134-A NFfVemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv0eZFqUUN3ME2wMlg{QTF{IN88US=> NVK2Nos2W0GQR1XS
SF268 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[0TWM2OD1yLki0NFQzKM7:TR?= NXPJUnVvW0GQR1XS
KARPAS-45 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGweGpKSzVyPUCuPFQzPjNizszN NX;PXHdbW0GQR1XS
TGW MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7FTWM2OD1yLki1PFY{KM7:TR?= NXHWOFBsW0GQR1XS
CHP-126 NWPzZ3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwOEW5OVch|ryP Mn\SV2FPT0WU
MOLT-16 NXG0R|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDu[5VKSzVyPUCuPFc2QDlizszN M1y5N3NCVkeHUh?=
LB771-HNC NYDzTnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnSUXo6UUN3ME2wMlg6PzV5IN88US=> NYPSZWRYW0GQR1XS
NALM-6 M1nUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHob2FzUUN3ME2wMlkxPzN7IN88US=> NEPWSolUSU6JRWK=
GCIY NWrkO4ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojGTWM2OD1yLkm1OVI3KM7:TR?= MVjTRW5ITVJ?
IST-MES1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwOUi4NlQh|ryP MlPhV2FPT0WU
LB2241-RCC NXjF[4hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHQTWM2OD1yLkm4PFQh|ryP NGXpOVVUSU6JRWK=
BL-70 NYe1V2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzrOJNKSzVyPUCuPVk2OzVizszN NYnQSIlrW0GQR1XS
NB17 Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMEC2N|kh|ryP NFz5dpVUSU6JRWK=
LXF-289 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwMEOwO|Yh|ryP M{H1VHNCVkeHUh?=
TK10 NXHIdFdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP2Nng4UUN3ME2xMlA2ODZ|IN88US=> M4nofHNCVkeHUh?=
K5 M3PYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HLfGlEPTB;MT6wOlI4PCEQvF2= M4PibXNCVkeHUh?=
NCI-H716 M{Dsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH0fIpVUUN3ME2xMlA4OjV7IN88US=> NEHRPVdUSU6JRWK=
HCE-T NUmxVIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTOTWM2OD1zLkC4PFE6KM7:TR?= M{HSSXNCVkeHUh?=
GI-1 M33JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[zbGlEPTB;MT6wPVc6QCEQvF2= NWTYTXBkW0GQR1XS
KARPAS-422 NXrBOZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj6T2dvUUN3ME2xMlExODJ{IN88US=> MmjTV2FPT0WU
TE-9 NFfIe|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLZcJpZUUN3ME2xMlEyOzJ6IN88US=> MYrTRW5ITVJ?
SF126 NYeyR3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7nWllKSzVyPUGuNVE2PjhizszN MnjaV2FPT0WU
BB30-HNC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r4eWlEPTB;MT6xN|EyOiEQvF2= M{e0NXNCVkeHUh?=
NCI-H1304 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zpOmlEPTB;MT6xN|M{QCEQvF2= NHTuRmdUSU6JRWK=
HEL MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfsZ5RbUUN3ME2xMlE1QDl3IN88US=> NEDSO4VUSU6JRWK=
HAL-01 M1m2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3HTWM2OD1zLkG1Nlg{KM7:TR?= MWHTRW5ITVJ?
SK-LMS-1 NHXCc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwMUW5O|Qh|ryP MnK5V2FPT0WU
SW954 M1PsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMUm1Olch|ryP MWTTRW5ITVJ?
D-283MED Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG4boMyUUN3ME2xMlIzOzd7IN88US=> NHvidZpUSU6JRWK=
NCI-H1882 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT2eoV1UUN3ME2xMlI{QDlizszN MnzvV2FPT0WU
GI-ME-N MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nGOmlEPTB;MT6yOVIxQCEQvF2= NUHp[mpMW0GQR1XS
SK-PN-DW MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMk[zOFgh|ryP MkTtV2FPT0WU
C2BBe1 M2m5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\6b5dKSzVyPUGuNlkyOTdizszN NYC4[41XW0GQR1XS
A704 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwM{K2PFkh|ryP MV3TRW5ITVJ?
KALS-1 NYm5OFZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWzZndKSzVyPUGuN|QxQCEQvF2= NVuzUmFPW0GQR1XS
ETK-1 M3\oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfpfXZKSzVyPUGuN|Q1QDlizszN MXnTRW5ITVJ?
LB647-SCLC Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknJTWM2OD1zLkO0PVg3KM7:TR?= M2LSTXNCVkeHUh?=
OCUB-M MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwM{[xOFMh|ryP NFK1eJVUSU6JRWK=
NCI-H720 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwM{[zO|gh|ryP M3HsZnNCVkeHUh?=
NB13 NUjhdIg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD1zLkO3Nlk{KM7:TR?= MYTTRW5ITVJ?
GR-ST M3nFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjNTmFKUUN3ME2xMlM5PzV5IN88US=> MXTTRW5ITVJ?
DU-4475 M2\JZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;YSmlEPTB;MT60OVg2OyEQvF2= NInuS|JUSU6JRWK=
HCC2157 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\WcpZwUUN3ME2xMlQ3PjV7IN88US=> MkP6V2FPT0WU
RKO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD1zLkS5PVIzKM7:TR?= M4DGR3NCVkeHUh?=
LS-123 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDSTWM2OD1zLkWxOVk1KM7:TR?= MoHCV2FPT0WU
NCI-H69 NUjwWpF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DpXWlEPTB;MT61OVgyOSEQvF2= M1vveHNCVkeHUh?=
SW962 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD1zLkW2NVMh|ryP NInvO|BUSU6JRWK=
PF-382 NI\YZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fJXWlEPTB;MT61Olk3KM7:TR?= NXnqWnpZW0GQR1XS
A101D NWr5dXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfXTm1KSzVyPUGuOVcyOTNizszN MVvTRW5ITVJ?
NB10 M2XoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG0TWM2OD1zLkW3N|kzKM7:TR?= NV\6Z4Y1W0GQR1XS
NB5 NWr0eWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT6XopKSzVyPUGuOVg1PzZizszN MX\TRW5ITVJ?
HCE-4 M2T6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTZoVKSzVyPUGuOlA5PSEQvF2= MkC1V2FPT0WU
HT-144 NYmxSmlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG1cll3UUN3ME2xMlY{OTlizszN MUjTRW5ITVJ?
NCI-H524 NWO3OXdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwNkSzNFch|ryP MlLlV2FPT0WU
NKM-1 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGyToRTUUN3ME2xMlY5PjZizszN M3;BcnNCVkeHUh?=
KURAMOCHI MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nwN2lEPTB;MT62PVU4OyEQvF2= MYXTRW5ITVJ?
NCI-H187 NYLz[JQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVniR2pYUUN3ME2xMlcxODN4IN88US=> NGfMTJNUSU6JRWK=
U-266 M1jSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;RTWM2OD1zLkezPFQzKM7:TR?= NGDXeoFUSU6JRWK=
BL-41 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrE[oZNUUN3ME2xMlc3Ojd{IN88US=> NIK0TmhUSU6JRWK=
SK-N-DZ NUH6NlBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwN{izNFkh|ryP NGXvV5lUSU6JRWK=
Daudi MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3bYNKSzVyPUGuO|g6PjdizszN MULTRW5ITVJ?
CPC-N NVLCfWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTYPXpnUUN3ME2xMlg2ODl4IN88US=> NXj1cotnW0GQR1XS
EM-2 M2LvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwOEWxJO69VQ>? NVG2dmxNW0GQR1XS
HCC1187 NID4WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfTUnhKSzVyPUGuPFYzPDFizszN NUDlN|VGW0GQR1XS
LP-1 M2ntOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;RTVJKSzVyPUGuPFcyPDNizszN Ml;uV2FPT0WU
CAS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1XGhKSzVyPUGuPVgzQTlizszN MkTJV2FPT0WU
NB7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwMEC1OVUh|ryP MlmzV2FPT0WU
VA-ES-BJ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMEG1NVMh|ryP NFfGUnpUSU6JRWK=
SNU-C2B MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwMEOzOVEh|ryP NV;XOVBuW0GQR1XS
LOXIMVI NGL6RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPm[2pwUUN3ME2yMlA3Pzh4IN88US=> NUTabpBbW0GQR1XS
NCI-H1581 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ezTWlEPTB;Mj6xNVU2QSEQvF2= MV7TRW5ITVJ?
IST-SL2 NXztdnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS0TWM2OD1{LkGyOFQ2KM7:TR?= MmXmV2FPT0WU
NOMO-1 NHy3[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMUe2PFMh|ryP MVvTRW5ITVJ?
TE-6 NFfhN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7YTWM2OD1{LkG5NFUh|ryP NFjJSGlUSU6JRWK=
NCI-H526 NVLt[ZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\H[2lKSzVyPUKuNVkyPDFizszN NWTtPFh4W0GQR1XS
MSTO-211H MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwMkCwOFEh|ryP MXXTRW5ITVJ?
LS-513 NVzMXop3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnXdWRuUUN3ME2yMlIzOjZ7IN88US=> M4DCOnNCVkeHUh?=
NCI-SNU-1 NILVZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P4eGlEPTB;Mj6zN|I2PiEQvF2= NUfZeGNoW0GQR1XS
BB65-RCC Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwM{e0PVMh|ryP NYjzc3ByW0GQR1XS
GT3TKB MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW5O5JKSzVyPUKuN|k6PzJizszN MYnTRW5ITVJ?
OS-RC-2 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojaTWM2OD1{LkSyN|QyKM7:TR?= Ml7ZV2FPT0WU
NCI-H2126 M2XYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6[4hKSzVyPUKuOFM3PzRizszN MXHTRW5ITVJ?
SK-UT-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL5TWM2OD1{LkS3OFY4KM7:TR?= MmHNV2FPT0WU
DMS-114 NWnidndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\JOlRXUUN3ME2yMlYyPTJ2IN88US=> NYXWSYVDW0GQR1XS
ONS-76 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwNkO2OFEh|ryP NInPepJUSU6JRWK=
8-MG-BA MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwNkW0NVQh|ryP MoPBV2FPT0WU
BOKU M{\nfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjWbHlKSzVyPUKuO|I4PjRizszN NUTQV5JNW0GQR1XS
LAMA-84 M3jRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;GbIlKSzVyPUKuO|k6OTJizszN NEnXOYpUSU6JRWK=
ES1 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHjfXdQUUN3ME2yMlgyQDB2IN88US=> NUTWTnVCW0GQR1XS
NCI-H1395 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTJTWM2OD1{LkiyNFEzKM7:TR?= MUHTRW5ITVJ?
A388 M{i0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni1TWM2OD1{Lkm2NVch|ryP NYjWZZNGW0GQR1XS
NCCIT NWruR5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwMEi4OlIh|ryP NIr2UVhUSU6JRWK=
HD-MY-Z NUCxeZNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HL[GlEPTB;Mz6xN|IxOyEQvF2= MWjTRW5ITVJ?
NCI-H510A M2r3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkNItKSzVyPUOuNVg6PDNizszN MXfTRW5ITVJ?
NCI-N87 NXv4c|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwMkCwNkDPxE1? NULSW3F6W0GQR1XS
SCLC-21H Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq2b3BJUUN3ME2zMlI3QDV7IN88US=> NHLqU|NUSU6JRWK=
SH-4 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3mXY9KSzVyPUOuNlg4QTdizszN NVzFTWF6W0GQR1XS
QIMR-WIL NWGwfYFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwM{K4OFkh|ryP NH7jTJhUSU6JRWK=
KM12 MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TqVWlEPTB;Mz6zN|U1PCEQvF2= NXvLVnpJW0GQR1XS
ST486 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv5fYdjUUN3ME2zMlU{QDh|IN88US=> M4fEPXNCVkeHUh?=
HC-1 M{PRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjuUGRKSzVyPUOuOlIxOjhizszN MUXTRW5ITVJ?
BV-173 M{jOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTUcHo1UUN3ME2zMlY1ODh6IN88US=> MWrTRW5ITVJ?
EW-24 M{DKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwNk[0N|Qh|ryP M3zwcnNCVkeHUh?=
LU-65 MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNwNki3NUDPxE1? M4\HcnNCVkeHUh?=
ECC4 NHHwWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlewTWM2OD1|Lke3OVYh|ryP NXrJO|ROW0GQR1XS
ARH-77 M1vnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jjV2lEPTB;ND6xNVA3PyEQvF2= M3HFNnNCVkeHUh?=
BC-3 NUPrSI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG3TWM2OD12LkGzNFY5KM7:TR?= MoXUV2FPT0WU
SNB75 Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\yTWM2OD12LkK2NVkh|ryP MnnQV2FPT0WU
MEG-01 M2jXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nLO2lEPTB;ND6yO|QyQSEQvF2= NH\uXXRUSU6JRWK=
NCI-H1417 NGnRNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4njTGlEPTB;ND6yPFQ1OyEQvF2= NHe2XXVUSU6JRWK=
MDA-MB-134-VI Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj3enV4UUN3ME20MlMxPjBzIN88US=> MXTTRW5ITVJ?
Becker MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTDe2hKSzVyPUSuOFc{OzZizszN Mk\vV2FPT0WU
DMS-153 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\CTWM2OD12Lk[2OFc2KM7:TR?= M3WzfXNCVkeHUh?=
TGBC1TKB NFnjfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;ve2lEPTB;ND62PFUyPSEQvF2= M364cHNCVkeHUh?=
EW-3 NVr4RWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoixTWM2OD12Lke2NlQ5KM7:TR?= Mn\3V2FPT0WU
KE-37 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjbWxKSzVyPUSuPFYyQTZizszN MXTTRW5ITVJ?
NCI-H23 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m5[GlEPTB;ND64O|IzPyEQvF2= M4jheXNCVkeHUh?=
MC116 NYru[4FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXrfFF5UUN3ME20Mlk1OTJ4IN88US=> NIm1[XNUSU6JRWK=
NH-12 NV:4U2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwOU[0N|kh|ryP NGjtOmZUSU6JRWK=
CTB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Wwd2lEPTB;ND65O|czOSEQvF2= M4P4[nNCVkeHUh?=
KM-H2 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXEWWpKSzVyPUWuNFU{OjNizszN Mmj0V2FPT0WU
MOLT-4 NXfDVGw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzTTWM2OD13LkGxPFMh|ryP M2fTVHNCVkeHUh?=
NCI-H2141 MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwMUSyOlgh|ryP NVjaUnVWW0GQR1XS
EB-3 NXT4PYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVwMUe1NFQh|ryP NYGwTGhJW0GQR1XS
NCI-H1522 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\WNGlEPTB;NT6yOlMzOiEQvF2= MXHTRW5ITVJ?
MRK-nu-1 M1jhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwNEO2N|Mh|ryP NU\aNGdFW0GQR1XS
no-11 M4XxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHVWJpKSzVyPUWuOFcxQDdizszN NXvKcYZYW0GQR1XS
CESS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ETWM2OD13LkW4NFM1KM7:TR?= NFfGXplUSU6JRWK=
KMOE-2 M1PNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDo[ZRmUUN3ME21MlU5PjV7IN88US=> M3nvcnNCVkeHUh?=
REH M4nRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5TWM2OD14LkK1OlE5KM7:TR?= MXTTRW5ITVJ?
KU812 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M372VmlEPTB;Nj60Nlc6OSEQvF2= NIXTOJlUSU6JRWK=
SK-N-FI M3TxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTsNFVKSzVyPU[uOlA3PzRizszN NYf1VGlkW0GQR1XS
MMAC-SF MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7LWGw4UUN3ME23MlA3PDl{IN88US=> NVnZ[GZxW0GQR1XS
RCC10RGB NV70[49yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwMkK5O|ch|ryP MkLlV2FPT0WU
NCI-H322M M2X0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XmWmlEPTB;Nz6zN|M{PSEQvF2= MnjEV2FPT0WU
NB6 NYqwNllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK5fZMyUUN3ME23MlU1QDl7IN88US=> NHjVZnVUSU6JRWK=
MN-60 NFXtVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTdwNkmyNVUh|ryP MoLLV2FPT0WU
NCI-H1092 NFzm[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17vUWlEPTB;OD6wNVc{PCEQvF2= M3zQeXNCVkeHUh?=
EKVX NGj3RVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jKcWlEPTB;OD60O|A3PiEQvF2= MYjTRW5ITVJ?
D-263MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2naTGlEPTB;OD61OVM6PiEQvF2= MonEV2FPT0WU
NCI-H209 NWDWfG0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRThwNkSwNFYh|ryP NUXYWndNW0GQR1XS
IST-SL1 M3\RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG0eXRtUUN3ME24Mlg6QDl{IN88US=> M{LtZnNCVkeHUh?=
ACN NFnnc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPH[Gt{UUN3ME25MlE6OTV5IN88US=> M1jEdHNCVkeHUh?=
MHH-PREB-1 M1naRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TpW2lEPTB;OT6yNVIyQSEQvF2= M2rXZnNCVkeHUh?=
EW-11 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O5[GlEPTB;OT62OVM6PiEQvF2= MnPkV2FPT0WU
KASUMI-1 NGizXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInZco9KSzVyPUmuO|g4PyEQvF2= MlftV2FPT0WU
KINGS-1 M4G0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TOUGlEPTB;MUCuNlM1PyEQvF2= NXL5UmNWW0GQR1XS
EVSA-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFyLkOxPVIh|ryP MojmV2FPT0WU
DSH1 NHLCWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:wWmdTUUN3ME2xNE4{QTd{IN88US=> NXXGRYJUW0GQR1XS
COLO-824 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDDTWM2OD1zMD64OlY6KM7:TR?= NYXzdlB{W0GQR1XS
K052 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD1zMD65N|IzKM7:TR?= MXrTRW5ITVJ?
SK-MEL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3jWnVKSzVyPUGwMlk6OzlizszN MonBV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
細胞アッセイ: [1]
+ 展開
  • 細胞株: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • 濃度: 1 nM-10 μM
  • 反応時間: 2–3 days
  • 実験の流れ: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (参考用のみ)
動物実験:[1]
+ 展開
  • 動物モデル: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • 製剤: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • 投薬量: 1, 3, and 10 mg/kg
  • 投与方法: Once daily by oral gavage for 3 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 3 mg/mL (4.88 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 30% PEG400+0.5% Tween80+5% propylene glycol, pH 4 10 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 614.2
化学式

C30H40ClN7O3S

CAS No. 761439-42-3
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

ALK信号経路図

ALK Inhibitors with Unique Features

相関ALK製品

Tags: TAE684 (NVP-TAE684)を買う | TAE684 (NVP-TAE684) ic50 | TAE684 (NVP-TAE684)供給者 | TAE684 (NVP-TAE684)を購入する | TAE684 (NVP-TAE684)費用 | TAE684 (NVP-TAE684)生産者 | オーダーTAE684 (NVP-TAE684) | TAE684 (NVP-TAE684)化学構造 | TAE684 (NVP-TAE684)分子量 | TAE684 (NVP-TAE684)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID